TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29327055

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, 125 mg/m2
Number of subjects: 695

Group type: COMPARATOR
Intervention: Paclitaxel, 90 mg/m2
Number of subjects: 695
Study: 26439786

Group type: EXPERIMENTAL
Intervention: 75% body mass sled pull
Number of subjects: 22

Group type: COMPARATOR
Intervention: 150% body mass sled pull
Number of subjects: 22

Group type: COMPARATOR
Intervention: 75% body mass sled pull vs 150% body mass sled pull
Number of subjects: 22
Study: 25265658

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard cardioprotective therapy
Number of subjects: 54
Study: 22659227

Group type: EXPERIMENTAL
Intervention: Automated voice reminders
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 598
Study: 19091821

Group type: EXPERIMENTAL
Intervention: Stapled anopexy (SA)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Closed haemorrhoidectomy (CH)
Number of subjects: 182
Study: 17167111

Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Other patients
Number of subjects: 86
Study: 16304122

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12190621

Group type: EXPERIMENTAL
Intervention: Ceramide 3‐containing emollient (Locobase(R) Repair)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control emollient (vaselinum album/cremor lanette ana)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 26
Study: 9618650

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 152

Group type: COMPARATOR
Intervention: Recent surgery
Number of subjects: 152

Group type: COMPARATOR
Intervention: Medical induction of remission
Number of subjects: 152
Study: 7631672

Group type: EXPERIMENTAL
Intervention: Increasing carbohydrate intolerance
Number of subjects: 3637
Study: 2695862

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/die/os for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (equivalent to pirenzepine for 12 weeks)
Number of subjects: 60
Study: 606771

Group type: EXPERIMENTAL
Intervention: Chemically disrupted influenza A/New Jersey/76 virus vaccine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Whole‐virus influenza A/New Jersey/76 virus vaccine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Preparation from Wyeth Laboratories
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Preparation from Parke, Davis and Company
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Preparation from Merrell‐National Laboratories
Number of subjects: 112
Study: 31117116

Group type: EXPERIMENTAL
Intervention: National strategy to reduce foodborne Campylobacter infection
Number of subjects: 39970

Group type: COMPARATOR
Intervention: Pre-2006 notification rates
Number of subjects: 39970

Group type: COMPARATOR
Intervention: Hospitalization rates pre-2006
Number of subjects: 39970

Group type: COMPARATOR
Intervention: Post-2008 age-standardized incidence rates
Number of subjects: 39970
Study: 27291563

Group type: EXPERIMENTAL
Intervention: Wheelchair basketball players
Number of subjects: 196
Study: 25994233

Group type: EXPERIMENTAL
Intervention: 3D model and reading materials on epitympanic anatomy
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2D group (reading material and pictures)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3D group (3D model and reading materials)
Number of subjects: 72
Study: 22773302

Group type: EXPERIMENTAL
Intervention: General combined epidural anesthesia (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine general anesthesia (Group A)
Number of subjects: 40
Study: 20127139

Group type: EXPERIMENTAL
Intervention: AZD6244 (100 mg twice daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Capecitabine (1,250 mg/m2 twice daily for 2 weeks followed by 1-week rest)
Number of subjects: 69
Study: 19169187

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200-400 mg/day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 17113759

Group type: EXPERIMENTAL
Intervention: Amisulpride (200-600 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Olanzapine (5-15 mg/day)
Number of subjects: 85
Study: 14729297

Group type: EXPERIMENTAL
Intervention: Intervention groups (three patient-focused interventions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (attention control and control group)
Number of subjects: 0
Study: 11584990

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMP-SMX (Trimethoprim-Sulfamethoxazole)
Number of subjects: 0
Study: 9389397

Group type: EXPERIMENTAL
Intervention: Octreotide (150 microg subcutaneously every 8 hours through postoperative day 5)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no further treatment after pancreaticoduodenectomy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reoperative pancreaticoduodenectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation
Number of subjects: 120
Study: 8187320

Group type: EXPERIMENTAL
Intervention: 96-hour fast with water freely available
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal hospital diet
Number of subjects: 6
Study: 3360052

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg p.o.
Number of subjects: 6
Study: 31969368

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 10 mg/kg plus pyridoxine for 12 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: No INH (Control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combined outcome of TB infection, disease and mortality
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses excluding infants with baseline TB-specific responses on flow cytometry
Number of subjects: 300
Study: 31626078

Group type: EXPERIMENTAL
Intervention: Passive intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 28610590

Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention with 2-week training in WHO Community Case Management followed by 12 months of CQI mentoring.
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group (no CQI intervention).
Number of subjects: 606
Study: 25223966

Group type: EXPERIMENTAL
Intervention: US-guided nerve block
Number of subjects: 400

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 400

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 400
Study: 23500314

Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning (RIPC) by cycles of inflation and deflation of the stent balloon during PCI
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning (RIPC)
Number of subjects: 225
Study: 22038744

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study: 16412796

Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (O-ET, 2 mg oral micronized 17beta estradiol daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (T-ET, 17beta estradiol 1.5 mg gel daily)
Number of subjects: 20
Study: 15256300

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (individual treatment session, two follow-up calls, information booklet)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standardised fact-sheet about infectious mononucleosis (control group)
Number of subjects: 69
Study: 11748518

Group type: EXPERIMENTAL
Intervention: Diltiazem (once-daily oral for at least 2 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not receiving diltiazem)
Number of subjects: 34
Study: 9286886

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 150

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 8379636

Group type: EXPERIMENTAL
Intervention: Double gloving (larger glove on the outside)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Double gloving (larger glove on the inside)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Double gloving (smaller glove on the outside)
Number of subjects: 17
Study: 3530302

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.50 mg triazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29351490

Group type: EXPERIMENTAL
Intervention: 25% Caloric Restriction (CR) for 24 months (n = 34)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ad libitum diet (AL) for 24 months (n = 19)
Number of subjects: 53
Study: 26268138

Group type: EXPERIMENTAL
Intervention: RP‐1127 (glyburide for injection)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25309754

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour
Number of subjects: 111
Study: 22773022

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 90
Study: 20613611

Group type: EXPERIMENTAL
Intervention: Temporalis muscle and facial flap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dermal graft
Number of subjects: 20
Study: 18076222

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training, 3 times per week for 8 weeks before ballet practice
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 22
Study: 16200849

Group type: EXPERIMENTAL
Intervention: 0.05 U/kg insulin (group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 0.1 U/kg insulin (group B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.05 U/kg insulin and 0.1 U/kg insulin
Number of subjects: 55
Study: 12145076

Group type: EXPERIMENTAL
Intervention: Lightwand (Trachlight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Direct laryngoscope (Macintosh blade)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngoscopy alone
Number of subjects: 60
Study: 10664918

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8737030

Group type: EXPERIMENTAL
Intervention: Combination treatment (daytime glibenclamide and evening NPH insulin)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intensive insulin treatment (rapid acting insulin before meals and NPH insulin at bedtime)
Number of subjects: 39
Study: 1433619

Group type: COMPARATOR
Intervention: Acute bolus intrathecal baclofen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chronic continuous intrathecal baclofen
Number of subjects: 10
Study: 3904543

Group type: EXPERIMENTAL
Intervention: IV aminophylline loading dose
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral aminophylline loading dose
Number of subjects: 19
Study: 30541073

Group type: EXPERIMENTAL
Intervention: Cervical cancer education techniques (symposium attendance or reading printed handouts)
Number of subjects: 432
Study: 29448917

Group type: COMPARATOR
Intervention: Triamcinolone
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 121
Study: 27542666

Group type: EXPERIMENTAL
Intervention: Patient-centered label (PCL) strategy
Number of subjects: 845
Study: 24885674

Group type: EXPERIMENTAL
Intervention: Comprehensive multidisciplinary care pathway
Number of subjects: 256

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 256
Study: 22230057

Group type: EXPERIMENTAL
Intervention: Custom PRK
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 40
Study: 20142784

Group type: EXPERIMENTAL
Intervention: Stronger power training (SP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weaker power training (WP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weaker strength training (WS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study: 18513639

Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15483562

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.038 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12521654

Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol + 2 mg dienogest (30EE/DNG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 2 mg dienogest (20EE/DNG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 microg ethinylestradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 100 microg levonorgestrel (EE/LNG)
Number of subjects: 100
Study: 10567752

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection
Number of subjects: 10
Study: 8733685

Group type: EXPERIMENTAL
Intervention: BCT
Number of subjects: 26
Study: 30770536

Group type: EXPERIMENTAL
Intervention: Live music therapy during rehabilitation
Number of subjects: 32

Group type: COMPARATOR
Intervention: No music during rehabilitation (Control)
Number of subjects: 32
Study: 28451784

Group type: EXPERIMENTAL
Intervention: Multicomponent program (Stand Up Victoria) with individual-, organisational-, and environmental-level change strategies; sit-stand workstations
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 231
Study: 27682068

Group type: EXPERIMENTAL
Intervention: Oral Fusidic Acid (FA) in combination with Oral Rifampin (RIF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) intravenous antibiotics
Number of subjects: 14
Study: 24748637

Group type: EXPERIMENTAL
Intervention: Oral vitamin D2 50,000 IU monthly for 24 weeks (Ca+D)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) alone (Ca)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ca+D
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ca
Number of subjects: 72
Study: 22699926

Group type: EXPERIMENTAL
Intervention: Structured wellness program (8 sessions of stress management)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 449
Study: 18212316

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding with conventional diabetes care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional diabetes therapy with a focus on weight loss by lifestyle change
Number of subjects: 60
Study: 16180593

Group type: EXPERIMENTAL
Intervention: Arm therapy programme (15‐20 45‐min sessions) based on repetition of unilateral and symmetrical bilateral tasks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual arm therapy of a similar duration and frequency to the experimental treatment
Number of subjects: 41
Study: 12966125

Group type: EXPERIMENTAL
Intervention: Shiga toxin-binding agent (500 mg/kg daily for 7 days)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo (cornmeal)
Number of subjects: 145
Study: 11005561

Group type: EXPERIMENTAL
Intervention: Plasma PAI‐1 levels
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Serum CRP levels
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Serum CRP
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Serum CRP (excluding Dukes' D disease)
Number of subjects: 594
Study: 9001924

Group type: EXPERIMENTAL
Intervention: Tepoxalin 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin 400 mg (multiple dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1623755

Group type: EXPERIMENTAL
Intervention: Supranormal hemodynamic and oxygen transport values
Number of subjects: 253

Group type: COMPARATOR
Intervention: Normal hemodynamic values
Number of subjects: 253
Study: 3883168

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Total mastectomy without axillary dissection but with regional irradiation
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Total mastectomy without irradiation plus axillary dissection if nodes were positive
Number of subjects: 1665
Study: 30869642

Group type: EXPERIMENTAL
Intervention: Stepped care with therapist-assisted I-CBT followed by f2f CBT if needed
Number of subjects: 363

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - face-to-face CBT
Number of subjects: 363
Study: 30202185

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 1018
Study: 27347792

Group type: EXPERIMENTAL
Intervention: Individual reminiscence sessions (5 weekly sessions)
Number of subjects: 41
Study: 25391143

Group type: EXPERIMENTAL
Intervention: Violent video game—offline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Violent video game—online
Number of subjects: 101

Group type: COMPARATOR
Intervention: Neutral video game—offline
Number of subjects: 101

Group type: COMPARATOR
Intervention: Neutral video game—online
Number of subjects: 101
Study: 22409644

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 10 weeks, supplemented with up to 4 caregiver educational sessions.
Number of subjects: 80
Study: 20207977

Group type: EXPERIMENTAL
Intervention: Two stents and cataract surgery (group 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cataract surgery alone (group 2)
Number of subjects: 33
Study: 19996048

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 715
Study: 15956632

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, 3 times daily for 1 year)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo (3 times daily for 1 year)
Number of subjects: 539
Study: 12591751

Group type: EXPERIMENTAL
Intervention: Heat stress (high skin and core temperatures)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal conditions (normal skin and core temperatures)
Number of subjects: 8
Study: 10579613

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg depot once every 28 days for four months, followed by additional cycles if menorrhagia occurred)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 72
Study: 8729530

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 24
Study: 1931534

Group type: EXPERIMENTAL
Intervention: Bioavail slow-release theophylline capsule
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7091036

Group type: EXPERIMENTAL
Intervention: Energy supplementation of 1000 kcal/day (group II)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Energy supplementation of 200 kcal/day (group I)
Number of subjects: 224
Study: 30238736

Group type: EXPERIMENTAL
Intervention: Vacuum Sealing Drainage (VSD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: External dressing (Control)
Number of subjects: 80
Study: 26460697

Group type: EXPERIMENTAL
Intervention: Home visiting parenting support program
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Father support satisfaction
Number of subjects: 428
Study: 24289920

Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24; or 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22344966

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD; 500 IU/250 mL, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain doogh (PD; no detectable vitamin D/250 mL, n=50)
Number of subjects: 100
Study: 19568826

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.4 mg/kg mean final dose)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 17646192

Group type: EXPERIMENTAL
Intervention: Women with ischaemic ECG changes
Number of subjects: 3143

Group type: COMPARATOR
Intervention: Men with ischaemic ECG changes
Number of subjects: 3143

Group type: EXPERIMENTAL
Intervention: Women with major ECG changes
Number of subjects: 3143

Group type: COMPARATOR
Intervention: Men with major ECG changes
Number of subjects: 3143

Group type: EXPERIMENTAL
Intervention: Definite CAD in women
Number of subjects: 3143

Group type: COMPARATOR
Intervention: Definite CAD in men
Number of subjects: 3143
Study: 15970067

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-8 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bendrofluazide (2.5 mg)
Number of subjects: 160
Study: 12584534

Group type: COMPARATOR
Intervention: PICC insertion
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Duration of PICC placement and line complications (blockage or leaking)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Retrieval of embolized line fragment
Number of subjects: 1650
Study: 11130295

Group type: EXPERIMENTAL
Intervention: Lifestyle influences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social deprivation
Number of subjects: 0